Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genscript Biotech ( (HK:1548) ) has shared an update.
Genscript Biotech has announced that its chairman and executive director, Jiange (Robin) Meng, has been appointed to the board of its associate company Legend Biotech Corporation, effective 20 January 2026, replacing outgoing director Li Zhu with a term running until Legend’s 2026 annual general meeting. The move strengthens board-level ties between Genscript and Legend, leveraging Meng’s extensive leadership, finance and corporate governance experience in the life sciences sector, and may enhance strategic coordination between the Hong Kong- and U.S.-listed companies, though investors are reminded to remain mindful of investment risks when trading Genscript’s shares.
The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a life sciences and biotechnology company listed in Hong Kong, providing products and services across the biotech value chain. The group has a strategic interest in Legend Biotech Corporation, a Nasdaq-listed associate focused on cell therapy and related biopharmaceutical innovations.
Average Trading Volume: 9,674,275
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.95B
For detailed information about 1548 stock, go to TipRanks’ Stock Analysis page.